Brightgene Bio-Medical Technology Co.,Ltd.’s Net Profit Dropped 0.6% in First Three Quarters of 2023

Brightgene Bio-Medical Technology Co.,Ltd. (博瑞生物医药(苏州)股份有限公司) (688166.SH) reported a net profit of 176.7 million yuan in the first three quarters of 2023, down 0.6% year-on-year.

Meanwhile, the company posted 914.9 million yuan in revenue, up 18.5% year-on-year.

At the end of the reporting period, it had 5 billion yuan in total assets and 2.5 billion yuan in total liabilities, with a liability-to-asset ratio of 50.9%.